TOMI Environmental Solutions, Inc.® (NASDAQ: TOMZ), a global company that specializes in disinfection and decontamination through the utilization of its premier Binary Ionization Technology (BIT) platform, today announced that it has received approximately $1.3 million of orders for its Custom Engineered Systems (CES) and have set installation dates for these systems. Two of the orders are from a Fortune 500 pharmaceuticals company and the other is from a leading research facility focused on immunology and infectious disease.

TOMI installed its first CES in 2016 for Dana Farber Cancer Institute and has installed an additional 6 units to date. The Company is seeing an increased pipeline of sales opportunities for the CES solution primarily due to higher numbers of cleanrooms being used by pharmaceutical and life science companies, as well as a shift from manual to automated disinfection to drive more efficiency and effectiveness. These customers choose TOMI’s CES solution because it eliminates human error, provides accuracy unmatched by competing solutions and reduces labor cost and down time.

Because TOMI’s CES solution is a highly customized product, there is typically a longer lead time from sale to manufacture and final installation. Design and technical concepts tailored to the specific needs of each customer must be established prior to manufacturing. The Company expects to realize revenue from these orders in late 2022 and early 2023.

Elissa (E.J.) Shane, TOMI’s COO, states, “We are now winning bids and replacing our competition for SteraMist to become their standard decontamination solution. We are experiencing an increased interest in our CES solution given the success of the products in the field, our growing reputation, and the increased number of cleanrooms in the pharmaceutical and life science sectors. We are in the process of expanding our technical and R&D team to prepare future projects and meet such growing demand. These are large, custom sales with long lead times, so the strong pipeline of opportunities positions us well to grow revenue from our CES product over the long term.”